Conjugate Vaccine Market

1. Coherent Market Insights Market Research and Business Consulting Services https://www.coherentmarketinsights.com/ COVID-19 Impact Tracker

2. CONJUGATE VACCINE MARKET ANALYSIS Conjugate Vaccine Market, by Product Types (Monovalent Conjugate Vaccines and Multivalent Conjugate Vaccine), by Disease Indication (Pneumococcal, Influenza, Meningococcal, and Typhoid), by Pathogen Type (Bacterial and Viral), by Patient Type (Pediatric and Adults), and by region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

3. Global Conjugate Vaccine Market InsightsIncreasing collaborations among key players to develop and introduce vaccines for pneumococcal and meningococcal diseases in the market and ongoing clinical trial studies on pneumococcal vaccines are expected to drive growth of the global conjugated vaccines market in the near future. For instance, in April 2018, Merck & Co, Inc. initiated two Phase III studies of PCV-15 (V114), an investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease.The global conjugate vaccine market was valued at US$ 12,977.2 million in 2018, and is expected to witness a CAGR of 9.6% during the forecast period (2018–2026).

4. Figure 1. Global Conjugate Vaccine Market value Analysis (US$ Mn), By Product Type

5. Increasing prevalence of various infectious diseases is expected to drive growth of the global conjugate vaccine market • According to World Health Organization (WHO), till November 2017, over 280 million people have been vaccinated with meningococcal A conjugate vaccine in 21 African belt countries. Moreover, increasing prevalence of meningococcal infections is a major factor expected to aid in growth of the global conjugate vaccine market. For instance, according to Centers for Disease Control and Prevention (CDC), in 2015, around 375 total cases of meningococcal disease were reported in the U.S. • Furthermore, development of multivalent conjugate vaccines by key players is expected to drive growth of global conjugate vaccine market. For instance, in September 2018, Pfizer, Inc. received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for its 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) candidate, PF-06482077. The candidate has been developed for the prevention of invasive disease and pneumonia, caused by Streptococcus pneumonia serotypes for adults aged 18 years and older. • Increasing approval for meningococcal conjugate vaccine candidates is expected to boost growth of the global conjugate vaccine market. For instance, in December 2016, Pfizer Inc. received an European Commission (EC) approval for its expanded indication for Nimenrix (meningococcal group A, C, W-135, and Y conjugate vaccine), which is indicated for active immunization against invasive meningococcal disease (IMD), caused by Neisseria meningitidis serogroups A, C, W-135, and Y (MenACWY) in infants as early as six weeks of age.

6. Global Conjugate vaccine Market- Regional Analysis • North America is expected to witness lucrative growth in the global conjugate vaccine market, owing to increasing prevalence of diseases in the U.S. For instance, according to National Health Interview Survey (NHIS) 2015 reports, risk of pneumococcal disease among adults aged 19-64 years were increased by 2.8% as compared 2014 in the U.S. Moreover, presence of major vaccines manufacturers such as Pfizer Inc. and others in the region is also expected to boost the regional market share during the forecast period • Asia Pacific is also expected to drive growth of the global conjugate vaccine market, owing to increasing initiatives by healthcare provider and hospitals. Moreover, various national governments in the region are focusing on vaccination programs to fulfil the demand. For instance, National Immunization Program by Queensland Government in Australia and Mission Indradhanush vaccination program in India work to provide vaccination among children throughout the respective nations. • Europe is expected to show significant growth rate, owing to rising initiatives by key players in development of conjugate vaccine systems for various purposes. For instance, in March 2015, Pfizer Inc. (U.S.) received the European Commission approval for an expanded indication for the use of Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) for prevention of pneumonia caused by the 13 pneumococcal serotypes in the vaccine in adults aged 18 years and older.

7. Figure 2: Global Conjugate Vaccine Market Value (US$ Mn), By Region (2026) Source: Coherent Market Insights Analysis (2019)

8. Global Conjugate Vaccine Market - Competitive Landscape • Key players operating in the global conjugate vaccine market include Sanofi S.A, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline plc, Bharat Biotech, Serum institute of India Pvt. Ltd., Biological E. Limited, and Bio-Med

9. Request Sample Report • Request Customization • Download PDF Brochure • Talk to Analyst • Buy Now • Reference: https://www.coherentmarketinsights.com/market-insight/conjugate-vaccine-market-2697

10. About Us Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis

11. Contact Us Mr. Shah Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1-206-701-67 Email : sales@coherentmarketinsights.com

12. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter https://www.coherentmarketinsights.com/